News
TBPH
10.76
0.00%
0.00
Theravance Biopharma, Inc. Announces Final Results of Tender Offer
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the final results of its Dutch auction tender offer (the "Offer") to purchase up to $95 million of its ordinary shares, par value $0.00001 per share (the "S...
PR Newswire · 11/22 21:15
Insider Sell: Theravance Biopharma
Insider Sell: Theravance Biopharma
MT Newswires · 11/22 16:22
BRIEF-Theravance Biopharma Announces Preliminary Results Of Tender Offer
Reuters · 11/18 11:02
Theravance Biopharma, Inc. Announces Preliminary Results of Tender Offer
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the preliminary results of its Dutch auction tender offer (the "Offer") to purchase up to $95 million of its ordinary shares, par value $0.00001 per share (...
PR Newswire · 11/18 11:00
Theravance Biopharma Reports Preliminary Results of Tender Offer
Theravance Biopharma Reports Preliminary Results of Tender Offer
MT Newswires · 11/18 06:22
Target To Rally 29%? Plus This Analyst Predicts $245 For IQVIA Holdings
Benzinga · 11/17 12:12
SVB Leerink Maintains Outperform on Theravance Biopharma, Raises Price Target to $14
Benzinga · 11/17 11:03
--SVB Securities Adjusts Price Target on Theravance Biopharma to $14 From $12, Maintains Outperform Rating
--SVB Securities Adjusts Price Target on Theravance Biopharma to $14 From $12, Maintains Outperform Rating
MT Newswires · 11/17 10:12
We Might See A Profit From Theravance Biopharma, Inc. (NASDAQ:TBPH) Soon
Theravance Biopharma, Inc. ( NASDAQ:TBPH ) is possibly approaching a major achievement in its business, so we would...
Simply Wall St. · 11/11 13:20
Theravance Biopharma GAAP EPS of -$0.21 misses by $0.18, revenue of $12.5M misses by $3.46M
Seekingalpha · 11/10 17:00
HC Wainwright & Co. Maintains Buy on Theravance Biopharma, Raises Price Target to $19
Benzinga · 11/08 11:34
--HC Wainwright Adjusts Price Target on Theravance Biopharma to $19 From $12, Maintains Buy Rating
--HC Wainwright Adjusts Price Target on Theravance Biopharma to $19 From $12, Maintains Buy Rating
MT Newswires · 11/08 11:07
BRIEF-Theravance Biopharma Inc Reports Third Quarter 2022 Financial Results
Reuters · 11/07 22:20
Theravance Biopharma Q3 EPS $(0.21) Misses $(0.18) Estimate, Sales $12.45M Beat $12.05M Estimate
Benzinga · 11/07 21:35
-- Earnings Flash (TBPH) THERAVANCE BIOPHARMA Reports Q3 Revenue $12.5M
-- Earnings Flash (TBPH) THERAVANCE BIOPHARMA Reports Q3 Revenue $12.5M
MT Newswires · 11/07 16:22
-- Earnings Flash (TBPH) THERAVANCE BIOPHARMA Reports Q3 Revenue $12.5M, vs. Street Est of $11.8M
-- Earnings Flash (TBPH) THERAVANCE BIOPHARMA Reports Q3 Revenue $12.5M, vs. Street Est of $11.8M
MT Newswires · 11/07 16:15
A Preview Of Theravance Biopharma's Earnings
Benzinga · 11/04 19:10
Theravance Biopharma Q3 2022 Earnings Preview
Seekingalpha · 11/04 17:36
Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 10/26 14:02
Theravance Biopharma to Present New Ampreloxetine Data in Neurogenic Orthostatic Hypotension at the 33rd International Symposium on the Autonomic Nervous System
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new ampreloxetine data in neurogenic orthostatic hypotension (nOH) will be presented at the 33rd International Symposium on the Autonomic Nervous System, a ...
PR Newswire · 10/25 10:00
More
Webull provides a variety of real-time TBPH stock news. You can receive the latest news about Theravance Bioph through multiple platforms. This information may help you make smarter investment decisions.
About TBPH
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the discovery, development and commercialization of respiratory medicines. The Company develops transformational medicines to improve the lives of patients suffering from respiratory illnesses. The Company's research is engaged in the areas of inflammation and immunology. Its Nezulcitinib (TD-0903) product is a lung-selective pan Janus-associated kinase inhibitor designed for inhaled delivery, is under development for treatment of acute lung injury associated with coronavirus disease 2019. The Company is also developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease. Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Velusetrag (TD-5108), Selective 5-HT4 Agonist (TD-8954).